Roivant-backed Pulmovant to Present Phase 2 Mosliciguat PHocus Data at ERS 2026
Sep 6, 2026, 1:06 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Upcoming ERS data readout for mosliciguat could re-rate a speculative asset if results look favorable; phase 2 readouts in pulmonary hypertension often lead to outsized moves when data meet or exceed expectations.
AI summary
What happened, with direct paths to the underlying reporting
Roivant's Pulmovant will present Phase 2 PHocus results for mosliciguat in PH-ILD at ERS 2026. The global, randomized, double-blind trial enrolled 135 adults; a positive read could de-risk the program, lift ROIV's valuation, attract potential Phase 3 consideration, and spur partnering discussions with pharma or biotech collaborators. The data readout could set the tone for ROIV shares over the next 1–2 quarters.
Phase 2 PHocus mosliciguat PH-ILD results to be presented Sept 8 at ERS 2026.
PHocus enrolled 135 PH-ILD patients in a randomized, double-blind, placebo-controlled trial.
Mosliciguat is an inhaled sGC activator with first-in-class potential.
ATMOS Phase 1b showed up to 38% mean PVR reduction.
Readout could influence ROIV value via Phase 3 expansion or partnerships.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
StockNews.AISignal intelligence